Data from early clinical trials with the first-generation IDH-mut inhibitors in gliomas demonstrated brain penetrance, target engagement, a favorable safety profile, and preliminary efficacy almost exclusively in patients with non-enhancing glioma. Here, IDH1 is linked to central nervous system cancer.